Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model
- 26 October 1999
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (22) , 12749-12753
Abstract
We have investigated the efficacy of a hairpin ribozyme targeting the 5′ leader sequence of HIV-1 RNA in a transgenic model system. Primary spleen cells derived from transgenic or control mice were infected with HIV-1/MuLV pseudotype virus. A significantly reduced susceptibility to infection in ribozyme-expressing transgenic spleen cells ( P = 0.01) was shown. Variation of transgene-expression levels between littermates revealed a dose response between ribozyme expression and viral resistance, with an estimated cut off value below 0.2 copies of hairpin ribozyme per cell. These findings open up possibilities for studies on ribozyme efficacy and anti-HIV-1 gene therapy.Keywords
This publication has 40 references indexed in Scilit:
- Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studiesGene Therapy, 1998
- Ribozyme therapeuticsNature Biotechnology, 1997
- Translating genomics information into therapeutics: A key role for oligonucleotidesNature Biotechnology, 1997
- Expression of small, therapeutic RNAs in human cell nucleiGene Therapy, 1997
- A Novel Ribozyme Target Site Located in the HIV-1NefOpen Reading FrameVirology, 1996
- Less Hype, More Biology Needed for Gene TherapyScience, 1995
- Transfer of an Anti-HIV-1 Ribozyme Gene into Primary Human LymphocytesHuman Gene Therapy, 1994
- Transgenic Mice with Antisense RNA against the Nucleocapsid Protein mRNA of Mouse Hepatitis Virus.Journal of Veterinary Medical Science, 1993
- Antisense RNA production in transgenic miceSomatic Cell and Molecular Genetics, 1990
- Ribozymes as Potential Anti-HIV-1 Therapeutic AgentsScience, 1990